Published 5 days ago • loading... • Updated 4 days ago

The Rise and Rise of Class Actions

On May 19, 2025, a federal court in Philadelphia authorized a legal notice about two class action settlements relating to prescription generic drugs in the U.S. From 2009 to 2019.
The settlements stem from allegations that Heritage Pharmaceuticals Inc., Apotex Corp., and other companies engaged in unlawful practices under federal and state competition regulations, resulting in higher costs for end-payers of certain generic medications.
The lawsuit includes third party payers such as insurers and employers with self-funded plans as plaintiffs and has preliminarily certified distinct settlement classes for Heritage and Apotex defendants.
The settlements total $58 million, with Heritage's group paying $10 million and Apotex agreeing to $48 million, and distributions will occur after court approval at an October 3, 2025 fairness hearing.
Potential class members may be affected and can find more information via www.GenericDrugsEndPayerSettlement.com or by calling 1-877-316-0171, while the lawsuit continues against non-settling defendants.

Insights by Ground AI

Does this summary seem wrong?

48 Articles

All

Left

Center

Right

Newsroom

Lean Right

The rise and rise of class actions

The entry of litigation funders – firms that pay the costs of people taking legal action in return for a percentage of any damages awarded – has seen class actions become a regular feature in the New Zealand courts.Some argue that class actions offer access to justice – allowing people whose claims may be too small to pursue on their own, to join together to bring a claim. Others say the class action process is open to abuse, with funders using …

4 days ago·Auckland, New Zealand

Read Full Article